Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial
出版年份 2018 全文链接
标题
Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial
作者
关键词
-
出版物
INTENSIVE CARE MEDICINE
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-06-19
DOI
10.1007/s00134-018-5229-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections
- (2016) Vien T. M. Le et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
- (2016) Andre C. Kalil et al. CLINICAL INFECTIOUS DISEASES
- Molecular quantification of bacteria from respiratory samples in patients with suspected ventilator-associated pneumonia
- (2016) M. Clavel et al. CLINICAL MICROBIOLOGY AND INFECTION
- Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice
- (2016) Chenguang Zhou et al. mAbs
- Staphylococcus aureus α toxin potentiates opportunistic bacterial lung infections
- (2016) Taylor S. Cohen et al. Science Translational Medicine
- Anti-Alpha-Toxin Monoclonal Antibody and Antibiotic Combination Therapy Improves Disease Outcome and Accelerates Healing in a Staphylococcus aureus Dermonecrosis Model
- (2014) Jamese J. Hilliard et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Anti-bacterial monoclonal antibodies: Back to the future?
- (2012) Martin B. Oleksiewicz et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- ADAM10 Mediates Vascular Injury Induced by Staphylococcus aureus α-Hemolysin
- (2012) Michael E. Powers et al. JOURNAL OF INFECTIOUS DISEASES
- Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004–2009
- (2011) Stephen P. Hawser et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Comparative Analysis of USA300 Virulence Determinants in a Rabbit Model of Skin and Soft Tissue Infection
- (2011) Scott D. Kobayashi et al. JOURNAL OF INFECTIOUS DISEASES
- Antibody responses in patients with invasive Staphylococcus aureus infections
- (2010) G. Jacobsson et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus -hemolysin-mediated cellular injury
- (2010) G. A. Wilke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Early- and Late-Onset Pneumonia: Is This Still a Useful Classification?
- (2009) P. Gastmeier et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prevention and Treatment of Staphylococcus aureus Pneumonia with a -Cyclodextrin Derivative
- (2009) B. E. Ragle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pathogenesis of Methicillin‐ResistantStaphylococcus aureusInfection
- (2008) Rachel J. Gordon et al. CLINICAL INFECTIOUS DISEASES
- Antibodies for the treatment of bacterial infections: current experience and future prospects
- (2008) Christopher Bebbington et al. CURRENT OPINION IN BIOTECHNOLOGY
- Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review
- (2008) Z. Athanassa et al. EUROPEAN RESPIRATORY JOURNAL
- Vaccine protection againstStaphylococcus aureuspneumonia
- (2008) Juliane Bubeck Wardenburg et al. JOURNAL OF EXPERIMENTAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started